Tirzepatide is a research-grade, long-acting incretin-based peptide engineered to engage both GIP and GLP-1 receptors, enabling simultaneous interrogation of two key metabolic signaling pathways. Its dual-agonist profile makes it a valuable tool for studying endocrine cross-talk, insulin signaling dynamics, and appetite- and weight-regulation mechanisms beyond single-receptor incretin analogues.
Research Significance
Dual activation of GIP and GLP-1 receptors for integrated incretin-pathway studies
Enables investigation of glucose regulation, insulin sensitivity, and β-cell signaling
Supports research into appetite control, satiety signaling, and energy-balance mechanisms
Useful for comparative studies versus single-agonist GLP-1–based peptides
Potential Research Applications
Metabolic and endocrine pathway research
Models of glucose homeostasis and insulin signaling
Appetite, satiety, and energy-expenditure investigations
Structure–activity and receptor-bias studies of incretin mimetics
Specifications
Form: Lyophilized peptide powder
Identity: Synthetic dual GIP/GLP-1 receptor agonist peptide
Storage: Store at −20 °C; once reconstituted, use promptly under sterile laboratory conditions
